Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

AstraZeneca

Status and phase

Completed

Phase 1

Conditions

Alzheimer´s Disease

Treatments

Drug: Radioligand (11C)AZD2184

Drug: Radioligand (11C)AZD2995

Study type

Interventional

Funder types

Industry

Identifiers

NCT00692705

D0180C00018

Eudract No. 2007-004842-33

Details and patient eligibility

About

The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease.

Enrollment

13 estimated patients

Sex

All

Ages

20 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Alzheimer´s Disease patients - 50-85 years- mild to moderate AD, clinical progression of AD over 12 months.
Healthy male volunteers: - Age 20-50 years, Body Mass Index: 18-30 kg/m2.
Clinically normal physical findings including normal blood pressure and pulse rate.

Exclusion criteria

Alzheimer´s Disease patients:
significant cerebrovascular disease or depression, central nervous system infarct or infection or lesions
clinically significant illness within 2 weeks before the study start.
administration of any investigational product with effect on brain beta amyloid levels within 3 months prior to study and/or participation in a PET investigation other than study D0180C00011 as part of a scientific study during the past 12 months,.
Healthy volunteers; - clinically significant illness within 2 weeks before the study start, history of psychiatric or somatic disease/condition that may interfere.- first degree relative with dementia. Obvious deterioration of memory functions.